KOMO Biosciences

Executive Summary

KOMO Biosciences is a San Diego-based preclinical biotechnology company focused on developing novel small molecule therapeutics that target protein-protein interactions (PPIs) for oncology and other diseases. Founded in 2018, the company leverages its proprietary platform to address historically undruggable targets, with the goal of expanding the therapeutic landscape beyond conventional small molecule approaches. To date, KOMO has raised venture capital from undisclosed investors and maintains a lean team of 10-50 employees. The company’s lead program is in preclinical development, targeting a validated oncology PPI, though specific details remain confidential. The broader pipeline includes additional undisclosed programs aimed at other high-value PPIs in oncology and beyond. As a preclinical entity, KOMO Biosciences faces significant technical and regulatory risks, but its focus on PPIs—a challenging yet high-reward area—positions it as a potential leader in the next wave of small molecule innovation. Near-term value depends on successful IND-enabling studies and securing partnerships or additional financing. The company’s management team includes experienced drug developers, though public information is limited. With no clinical data or regulatory milestones yet achieved, KOMO represents a high-risk, high-reward opportunity for investors seeking exposure to early-stage PPI-targeted therapeutics.

Upcoming Catalysts (preview)

• Q2 2027IND Filing for Lead Oncology Program40% success
• Q4 2026Series A / Series B Financing Announcement60% success
• Q2 2026Preclinical Data Presentation at Major Oncology Conference50% success